Biotech startups that raised a seed round in the United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Welltory | Redwood City | Seed | $2.0M | 2026-10-08 |
| Talus Bio | Seattle | Seed | $11.2M | 2026-09-21 |
| heXem bio | New York | Seed | $10.4M | 2026-09-15 |
| PGxAI | Palo Alto | Seed | $3.0M | 2026-09-14 |
| Navion Neurosciences | Charlottesville | Seed | $10.8M | 2026-09-09 |
| Cloverleaf Bio | New Haven | Seed | $33.0M | 2026-09-08 |
| INIA Biosciences | Boston | Seed | $1.5M | 2026-09-08 |
| Rybodyn | San Diego | Seed | $1.3M | 2026-07-23 |
8 rows of the CSV in 5 of its 18 columns.
| Company | Person | Title | Verified email | |
|---|---|---|---|---|
| Eugit Therapeutics, Inc | G••• A••• | General Partner | g•••@ycombinator.com | In the CSV |
| AVLab | B••• B••• | Founder, Managing Partner | b•••@analyticsventures.com | In the CSV |
| Prime Movers Lab | A••• K••• | General Partner & Chief Investment Officer - Satori Neuro | a•••@primemoverslab.com | In the CSV |
3 verified founder and CEO contact rows from organizations on this list, names and emails masked.
- The 1,942 biotech startups in the United States whose last round is a seed round have raised $6.7B in total.
- 267 of them closed their most recent round in the last 12 months, $1.8B combined.
- The largest of those rounds is Merge Labs' $252.0M seed round, dated January 2026.
- The most recent is Zhiyan Zaowu's $7.5M seed round on 9 November 2026.
- Y Combinator is an investor in 30 of them, more than any other fund.
- Health care is the most common other sector, with 1,508 companies (78%).
- 37% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 1 to 10 employees (66% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 1,942| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Welltory | Welltory produces AI-powered wellness apps for digital health tracking. | Artificial intelligence | Redwood City | Seed | $2.0M | 2026-10-08 | $16.3M | Goodwater Capital, JOINT JOURNEY, CABRA VC | 51 to 100 | 2016 |
| Talus Bio | Talus Bio develops AI-driven drugs that target transcription factors considered undruggable. | Artificial intelligence | Seattle | Seed | $11.2M | 2026-09-21 | $27.8M | Y Combinator, Pioneer Fund, National Science Foundation +2 | 11 to 50 | 2020 |
| heXem bio | HexemBio develops a synthetic human Yolk Sac platform to rejuvenate blood stem cells and extend healthy lifespan. | Biotech | New York | Seed | $10.4M | 2026-09-15 | $10.4M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2024 |
| PGxAI | PGxAI provides a clinical decision support platform for pharmacogenomics, medication safety, and real-world evidence. | Artificial intelligence | Palo Alto | Seed | $3.0M | 2026-09-14 | $5.0M | ATEM Capital Fund LP | 11 to 50 | 2023 |
| Navion Neurosciences | Navion Neurosciences develops sodium channel therapeutics for neurological diseases at a pre-clinical stage. | Artificial intelligence | Charlottesville | Seed | $10.8M | 2026-09-09 | $21.2M | Virginia Innovation Partnership Corporation, 3B Future Health Fund, UVA Licensing & Ventures Group +1 | 1 to 10 | 2021 |
| Cloverleaf Bio | Cloverleaf Bio develops an RNA therapeutic platform for oncology. | Biotech | New Haven | Seed | $33.0M | 2026-09-08 | $33.0M | Mission BioCapital | 1 to 10 | 2023 |
| INIA Biosciences | INIA Biosciences develops non-invasive, home-administered medical devices to manage chronic inflammatory diseases. | Biotech | Boston | Seed | $1.5M | 2026-09-08 | $1.5M | MassChallenge, MedTech Innovator | 1 to 10 | 2020 |
| Rybodyn | Rybodyn develops therapeutics that train the immune system to detect and eradicate cancer. | Biotech | San Diego | Seed | $1.3M | 2026-07-23 | $15.3M | SOSV, SOSV SF & NY (Fka IndieBio) | 11 to 50 | 2022 |
| ElectroKare | ElectroKare builds computational models that simulate human physiological systems and processes. | Artificial intelligence | New York | Seed | $4.0M | 2026-07-01 | $4.0M | iVenture Accelerator, Techstars Physical Health, Fort Worth, Texas | 11 to 50 | 2025 |
| Portal | Portal engineers cells to develop new treatments and therapies. | Biotech | Watertown | Seed | $9.0M | 2026-06-18 | $25.7M | Pear VC, Page One Ventures, IA Ventures +2 | 11 to 50 | 2023 |
| Kopra Bio | Kopra Bio develops viral immunotherapy treatments to cure cancer. | Biotech | San Francisco | Seed | $9.1M | 2026-06-16 | $9.7M | Y Combinator, Pioneer Fund | 1 to 10 | 2024 |
| Kimba | Kimba uses AI to analyze biometric data and deliver personalized scent treatments for better sleep and health. | Artificial intelligence | New York | Seed | $5.4M | 2026-06-16 | $6.4M | Techstars | 1 to 10 | 2024 |
| Century Health | Century Health applies AI to real-world clinical data to accelerate drug development and commercialization. | Artificial intelligence | New York | Seed | $5.0M | 2026-05-19 | $7.0M | Alumni Ventures, Everywhere Ventures, 2048 Ventures +1 | 1 to 10 | 2023 |
| Auxilium Health | Auxilium Health develops low-cost, smart biomaterials for wounds that are difficult to heal. | Biotech | Akron | Seed | $3.0M | 2026-05-15 | $5.0M | Ohio Third Frontier | 1 to 10 | 2022 |
| ParcelBio | ParcelBio develops RNA medicine delivery systems and therapeutic development platforms. | Biotech | San Francisco | Seed | $13.0M | 2026-05-07 | $13.5M | Y Combinator, Alumni Ventures, Pioneer Fund +2 | 1 to 10 | 2024 |
| Modicus Prime | Modicus Prime enables pharmaceutical manufacturers to deploy auditable and compliant AI systems. | Artificial intelligence | Austin | Seed | $4.5M | 2026-05-06 | $9.2M | Techstars, Plug and Play, Alumni Ventures +2 | 11 to 50 | 2020 |
| Fermeate | Fermeate provides photomolecular fermentation technology that makes biomanufacturing more sustainable and efficient. | Biotech | San Francisco | Seed | $2.5M | 2026-04-27 | $2.5M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2024 |
| TippingPoint Biosciences | TippingPoint Biosciences develops therapeutics that target genome packaging states in diseases such as cancer. | Biotech | San Francisco | Seed | $4.5M | 2026-03-31 | $4.5M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2022 |
| BioLattice | BioLattice develops tissue healing solutions. | Biotech | Philadelphia | Seed | $575K | 2026-03-30 | $585K | SOSV, SOSV SF & NY (Fka IndieBio), Startup302 | 1 to 10 | 2017 |
| Gelmedix | Gelmedix develops a biomaterial platform that improves drug delivery for complex eye treatments. | Biotech | Newton | Seed | $13.0M | 2026-02-17 | $15.4M | Safar Partners, EQx Fund, HTL Innovations | 1 to 10 | 2020 |
| Avenue Biosciences | Avenue Biosciences is a transatlantic biotech company specializing in protein engineering technologies. | Biotech | Palo Alto | Seed | $7.4M | 2026-01-12 | $9.9M | Inventure, Voima Ventures | 11 to 50 | 2023 |
| NANOCHON | Nanochon develops medical implant technology for repairing cartilage in patients with joint surface damage. | Biotech | Washington | Seed | $4.1M | 2026-01-12 | $14.3M | Alumni Ventures, MassChallenge, National Science Foundation +2 | 1 to 10 | 2016 |
| STRM.BIO | STRM.BIO is a biotechnology company that uses extracellular vesicles to deliver gene therapy. | Biotech | Cambridge | Seed | $8.0M | 2026-01-07 | $10.1M | Bill & Melinda Gates Foundation, NYBC Ventures, NCATS | 11 to 50 | 2019 |
| Ligo Biosciences | Ligo Biosciences develops deep-learning models for enzyme design to lower the cost of chemical manufacturing. | Biotech | San Francisco | Seed | $500K | 2026-01-01 | $500K | Y Combinator | 1 to 10 | 2024 |
| 1849 Bio | 1849 Bio creates microbes that extract metals affordably from low-grade copper and gold ores. | Biotech | San Francisco | Seed | $500K | 2026-01-01 | $500K | Y Combinator | 1 to 10 | 2024 |
| Biometry | Biometry develops diagnostic tools for patients with chronic respiratory conditions. | Artificial intelligence | Boston | Seed | $2.2M | 2025-12-19 | $7.8M | MassChallenge, Elevate Ventures, Sidecar Angels +1 | 11 to 50 | 2013 |
| Feanix Biotechnologies | Feanix Biotechnologies operates a genetic laboratory that tests samples. | Biotech | Asheville | Seed | $5.3M | 2025-12-18 | $5.8M | Y Combinator | 11 to 50 | 2024 |
| Cayuga Biotech | Cayuga Biotech develops hemostatic drugs and devices for treating bleeding episodes. | Biotech | Bridgewater | Seed | $5.0M | 2025-12-11 | $8.2M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2015 |
| NeuroBionics | NeuroBionics develops bioelectronic medicine devices that treat disease by modulating nerve activity. | Biotech | Cambridge | Seed | $4.2M | 2025-12-10 | $9.2M | MedTech Innovator, Dolby Family Ventures, GreyMatter +1 | 1 to 10 | 2023 |
| OncoPrecision | OncoPrecision develops patient-centric therapeutic antibodies. | Biotech | New York | Seed | $4.5M | 2025-11-24 | $11.1M | SOSV, SOSV SF & NY (Fka IndieBio), GRID EXPONENTIAL +2 | 11 to 50 | 2020 |
Table 1. Biotech startups that raised a seed round in the United States: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 1,942.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cloverleaf Bio | Cloverleaf Bio develops an RNA therapeutic platform for oncology. | Biotech | New Haven | Seed | $33.0M | 2026-09-08 | $33.0M | Mission BioCapital | 1 to 10 | 2023 |
| 2 | ParcelBio | ParcelBio develops RNA medicine delivery systems and therapeutic development platforms. | Biotech | San Francisco | Seed | $13.0M | 2026-05-07 | $13.5M | Y Combinator, Alumni Ventures, Pioneer Fund +2 | 1 to 10 | 2024 |
| 3 | Gelmedix | Gelmedix develops a biomaterial platform that improves drug delivery for complex eye treatments. | Biotech | Newton | Seed | $13.0M | 2026-02-17 | $15.4M | Safar Partners, EQx Fund, HTL Innovations | 1 to 10 | 2020 |
| 4 | Talus Bio | Talus Bio develops AI-driven drugs that target transcription factors considered undruggable. | Artificial intelligence | Seattle | Seed | $11.2M | 2026-09-21 | $27.8M | Y Combinator, Pioneer Fund, National Science Foundation +2 | 11 to 50 | 2020 |
| 5 | Navion Neurosciences | Navion Neurosciences develops sodium channel therapeutics for neurological diseases at a pre-clinical stage. | Artificial intelligence | Charlottesville | Seed | $10.8M | 2026-09-09 | $21.2M | Virginia Innovation Partnership Corporation, 3B Future Health Fund, UVA Licensing & Ventures Group +1 | 1 to 10 | 2021 |
| 6 | heXem bio | HexemBio develops a synthetic human Yolk Sac platform to rejuvenate blood stem cells and extend healthy lifespan. | Biotech | New York | Seed | $10.4M | 2026-09-15 | $10.4M | SOSV, SOSV SF & NY (Fka IndieBio) | 1 to 10 | 2024 |
| 7 | Kopra Bio | Kopra Bio develops viral immunotherapy treatments to cure cancer. | Biotech | San Francisco | Seed | $9.1M | 2026-06-16 | $9.7M | Y Combinator, Pioneer Fund | 1 to 10 | 2024 |
| 8 | Portal | Portal engineers cells to develop new treatments and therapies. | Biotech | Watertown | Seed | $9.0M | 2026-06-18 | $25.7M | Pear VC, Page One Ventures, IA Ventures +2 | 11 to 50 | 2023 |
| 9 | STRM.BIO | STRM.BIO is a biotechnology company that uses extracellular vesicles to deliver gene therapy. | Biotech | Cambridge | Seed | $8.0M | 2026-01-07 | $10.1M | Bill & Melinda Gates Foundation, NYBC Ventures, NCATS | 11 to 50 | 2019 |
| 10 | Avenue Biosciences | Avenue Biosciences is a transatlantic biotech company specializing in protein engineering technologies. | Biotech | Palo Alto | Seed | $7.4M | 2026-01-12 | $9.9M | Inventure, Voima Ventures | 11 to 50 | 2023 |
Table 2. Biotech startups that raised a seed round in the United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Y Combinator | Startup accelerator | Mountain View, United States | 30 | 2% | 7 | Talus Bio, Kopra Bio, ParcelBio |
| 2 | SOSV | Venture capital firm | Princeton, United States | 23 | 1% | 9 | heXem bio, Farm Minerals, Rybodyn |
| 3 | SOSV SF & NY (Fka IndieBio) | Venture capital firm | San Francisco, United States | 20 | 1% | 9 | heXem bio, Farm Minerals, Rybodyn |
| 4 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 18 | 1% | 2 | Talus Bio, NANOCHON |
| 5 | Pioneer Fund | Startup accelerator | Toronto, Canada | 11 | 1% | 4 | Talus Bio, Kopra Bio, ParcelBio |
| 6 | Alumni Ventures | Angel group | Manchester, United States | 10 | 1% | 4 | Century Health, ParcelBio, Modicus Prime |
| 7 | MassChallenge | Startup accelerator | Boston, United States | 8 | 0% | 3 | INIA Biosciences, NANOCHON, Biometry |
| 8 | Techstars | Startup accelerator | New York, United States | 8 | 0% | 2 | Kimba, Modicus Prime |
| 9 | Plug and Play | Startup accelerator | Sunnyvale, United States | 7 | 0% | 2 | WittGen Biotechnologies, Modicus Prime |
| 10 | MedTech Innovator | Startup accelerator | Los Angeles, United States | 5 | 0% | 3 | INIA Biosciences, NANOCHON, NeuroBionics |
| 11 | Creative Destruction Lab | Entrepreneurship program | Toronto, Canada | 5 | 0% | 1 | NANOCHON |
| 12 | Right Side Capital Management | Micro VC fund | San Francisco, United States | 5 | 0% | ||
| 13 | Alchemist Accelerator | Startup accelerator | San Francisco, United States | 5 | 0% | ||
| 14 | Newchip Accelerator | Startup accelerator | Austin, United States | 5 | 0% | ||
| 15 | gbeta | Startup accelerator | Madison, United States | 4 | 0% |
Table 3. Biotech startups that raised a seed round in the United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 1,508 | 78% | $5.0B |
| Software | 340 | 18% | $2.0B |
| Artificial intelligence | 213 | 11% | $1.4B |
| Hardware | 61 | 3% | $321.2M |
| Energy | 27 | 1% | $32.6M |
| Fintech | 25 | 1% | $58.2M |
| Cybersecurity | 24 | 1% | $75.8M |
| Commerce | 16 | 1% | $25.9M |
| Education | 13 | 1% | $83.7M |
Table 4. Biotech startups that raised a seed round in the United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Seed | 1,942 | 100% | $957K |
Table 5. Biotech startups that raised a seed round in the United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| San Francisco | 172 | 9% |
| New York | 121 | 6% |
| Boston | 73 | 4% |
| Cambridge | 66 | 3% |
| San Diego | 64 | 3% |
| Palo Alto | 30 | 2% |
| Los Angeles | 30 | 2% |
| Berkeley | 27 | 1% |
| Houston | 27 | 1% |
| Seattle | 26 | 1% |
| Philadelphia | 25 | 1% |
| Chicago | 24 | 1% |
Table 6. Biotech startups that raised a seed round in the United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 3 | 1% | $11.0M |
| October 2026 | 26 | 10% | $279.2M |
| September 2026 | 31 | 12% | $204.5M |
| August 2026 | 20 | 7% | $102.8M |
| July 2026 | 21 | 8% | $43.3M |
| June 2026 | 22 | 8% | $122.4M |
| May 2026 | 25 | 9% | $85.9M |
| April 2026 | 20 | 7% | $50.8M |
| March 2026 | 15 | 6% | $193.1M |
| February 2026 | 16 | 6% | $45.3M |
| January 2026 | 39 | 15% | $451.5M |
| December 2025 | 20 | 7% | $146.5M |
| November 2025 | 9 | 3% | $43.2M |
Table 7. Biotech startups that raised a seed round in the United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 238 | 12% | $1.6B |
| 2025 | 211 | 11% | $957.3M |
| 2024 | 165 | 8% | $733.6M |
| 2023 | 143 | 7% | $479.1M |
| 2022 | 138 | 7% | $296.5M |
| 2021 | 147 | 8% | $321.4M |
Table 8. Biotech startups that raised a seed round in the United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 342 | 18% |
| 2020 to 2022 | 365 | 19% |
| 2015 to 2019 | 577 | 30% |
| 2010 to 2014 | 344 | 18% |
| Before 2010 | 265 | 14% |
Table 9. Biotech startups that raised a seed round in the United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 1,210 | 66% |
| 11 to 50 | 553 | 30% |
| 51 to 100 | 43 | 2% |
| 101 to 250 | 14 | 1% |
| 251 to 500 | 6 | 0% |
| 501 to 1,000 | 9 | 0% |
| 1,001 to 5,000 | 3 | 0% |
| 5,001 to 10,000 | 1 | 0% |
| 10,001 or more | 6 | 0% |
Table 10. Biotech startups that raised a seed round in the United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is a seed round and its headquarters is in the United States. On 16 November 2026 that is 1,942 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 1,942 rows: 563 have no round amount, 0 no city and 472 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in the United States whose last round is a seed round are on the list?
- 1,942, in the file dated 16 November 2026. 267 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 1,942 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.